Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network.

Auteurs : Morgan G, Tagliamento M, Lambertini M, Devnani B, Westphalen B, Dienstmann R, Bozovic-Spasojevic I, Calles A, Criscitiello C, Curioni A, Garcia AM, Lamarca A, Pilotto S, Scheffler M, Strijbos M, Wong R, de Azambuja E, Peters S
Jaar : 2021
Journal : ESMO Open
Volume : 6
Pagina's : 100104

OncoAlert Round Table Discussions: The Global COVID-19 Experience.

Auteurs : Morgan G, de Azambuja E, Punie K, Ades F, Heinrich K, Personeni N, Rahme R, Ferrara R, Pels K, Garassino M, von Bergwelt-Baildon M, Lopes G, Barlesi F, Choueiri TK, Burris H, Peters S
Jaar : 2021
Journal : JCO Glob Oncol
Volume : 7
Pagina's : 455-463

Emerging Therapeutics for Patients with Triple-Negative Breast Cancer.

Auteurs : Agostinetto E, Eiger D, Punie K, de Azambuja E
Jaar : 2021
Journal : Curr Oncol Rep
Volume : 23
Pagina's : 57

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

Auteurs : Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, Korde L, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Guillaume S, Ewer MS, Shao Z, Sim SH, Aziz Z, Demetriou G, Mehta AO, Andersson M, Toi M, Lang I, Xu B, Smith IE, Barrios CH, Baselga J, Gelber Rd, Piccart-Gebhart M
Jaar : 2021
Journal : Eur J Cancer
Volume : 148
Pagina's : 287-296

The Exciting New Field of HER2-Low Breast Cancer Treatment.

Auteurs : Eiger D, Agostinetto E, Saude Conde R, de Azambuja E
Jaar : 2021
Journal : Cancers (Basel)
Volume : 13

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience.

Auteurs : Franzoi MA, Saude Conde R, Ferreira SC, Eiger D, Awada A, de Azambuja E
Jaar : 2021
Journal : Breast
Volume : 57
Pagina's : 86-94

Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.

Auteurs : Lambertini M, Poggio F, Bruzzone M, Conte B, Bighin C, de Azambuja E, Giuliano M, De Laurentiis M, Cognetti F, Fabi A, Bisagni G, Durando A, Turletti A, Urracci Y, Garrone O, Puglisi F, Montemurro F, Ceppi M, Del Mastro L
Jaar : 2020
Journal : Int J Cancer
Volume : 147
Pagina's : 160-169

Post-Mastectomy Radiation Therapy in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients: Analysis of the HERA Trial.

Auteurs : Abi Jaoude J, de Azambuja E, Makki M, Tamim H, Tfayli A, Geara F, Piccart-Gebhart M, Poortmans P, Zeidan YH
Jaar : 2020
Journal : Int J Radiat Oncol Biol Phys
Volume : 106
Pagina's : 503-510

A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.

Auteurs : de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, Ballman K, Aspitia AM, Zardavas D, Roca L, Gelber Rd, Piccart-Gebhart M, Suter T
Jaar : 2020
Journal : Breast Cancer Res Treat
Volume : 179
Pagina's : 161-171

Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?

Auteurs : Caparica R, de Angelis C, Fêde Â, Werutsky G, de Azambuja E
Jaar : 2020
Journal : Expert Rev Anticancer Ther
Volume : 20
Pagina's : 563-573

HER2-positive advanced breast cancer treatment in 2020.

Auteurs : Cesca MG, Vian L, Cristóvão-Ferreira S, Pondé N, de Azambuja E
Jaar : 2020
Journal : Cancer Treat Rev
Volume : 88
Pagina's : 102033

ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.

Auteurs : de Azambuja E, Trapani D, Loibl S, Delaloge S, Senkus E, Criscitiello C, Poortman P, Gnant M, Di Cosimo S, Cortes J, Cardoso F, Paluch-Shimon S, Curigliano G
Jaar : 2020
Journal : ESMO Open
Volume : 5

Targeted therapy for breast cancer in older patients.

Auteurs : Pondé N, Wildiers H, Awada A, de Azambuja E, Deliens C, Dal Lago L
Jaar : 2020
Journal : J Geriatr Oncol
Volume : 11
Pagina's : 380-388

Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months.

Auteurs : de Las Heras B, Saini KS, Boyle F, Ades F, de Azambuja E, Bozovic-Spasojevic I, Romano M, Capelan M, Prasad R, Pattu P, Massard C, Portera C, Saini ML, Singh BP, Venkitaraman R, McNally R, Leone M, Grande E, Gupta S
Jaar : 2020
Journal : Oncol Ther
Volume : 8
Pagina's : 171-182

Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.

Auteurs : Desmedt C, Fornili M, Clatot F, Demicheli R, De Bortoli D, Di Leo A, Viale G, de Azambuja E, Crown J, Francis PA, Sotiriou C, Piccart-Gebhart M, Biganzoli E
Jaar : 2020
Journal : J Clin Oncol
Volume : 38
Pagina's : 2883-2891

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.

Auteurs : Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las Heras B, de Castro J, Lamba Saini M, Loibl S, Curigliano G, Twelves C, Leone M, Patnaik MM
Jaar : 2020
Journal : Br J Cancer
Volume : 123
Pagina's : 694-697

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.

Auteurs : Di Cosimo S, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart-Gebhart M, Huober J, Izquierdo M, de la Pena L, Hilbers FS, de Azambuja E, Untch M, Pusztai L, Pritchard K, Nuciforo P, Vincent-Salomon A, Symmans F, Apolone G, De Braud FG, Iorio MV, Verderio P, Daidone MG
Jaar : 2020
Journal : Int J Mol Sci
Volume : 21

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

Auteurs : Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, Armenian S, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K
Jaar : 2020
Journal : Ann Oncol
Volume : 31
Pagina's : 171-190

Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.

Auteurs : Pondé N, Ameye L, Lambertini M, Paesmans M, Piccart-Gebhart M, de Azambuja E
Jaar : 2020
Journal : Eur J Cancer
Volume : 126
Pagina's : 65-73

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Auteurs : Bines J, Procter M, Restuccia E, Viale G, Zardavas D, Suter T, Arahmani A, van Dooren V, Baselga J, Clark E, Eng-Wong J, Gelber Rd, Piccart-Gebhart M, Mobus V, de Azambuja E
Jaar : 2020
Journal : Clin Breast Cancer
Volume : 20
Pagina's : 174-181.e3